| Literature DB >> 18675506 |
Feng Tian1, Longxin Wang, Weijun Qin, Fuli Wang, Bin Song, Yu Li, Weihong Wen, Zheng Zhang, Kaichang Zhu, Qiang Zhang, Chung Lee, Weide Zhong, Yinglu Guo, He Wang.
Abstract
Dendritic cells (DCs) have been widely used as cancer vaccines. However, their functional abilities have often been suppressed by tumor-secreted immunosuppressants such as transforming growth factor-beta (TGF-beta). We developed a new strategy using a TGF-beta insensitive DC as cancer vaccine. The effect of this vaccine was tested in a murine pulmonary metastases model of renal carcinoma (Renca). Tumor lysate-pulsed DCs (TP-DCs) were infected with retrovirus containing gene of dominant negative TGF-beta type II receptor (TbetaRIIDN) and thus made TGF-beta insensitive. Vaccination of the mice bearing Renca pulmonary metastases with the TbetaRIIDN TP-DC induced powerful tumor-specific cytotoxic T lymphocyte (CTL) responses, suppressed pulmonary metastases, and prolonged survival times. These results suggest TGF-beta-insensitive TP-DC vaccine can be used to enhance the antitumor efficacy of DC vaccine.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18675506 DOI: 10.1016/j.canlet.2008.06.025
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679